Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409488 | 0.85 | ADRB2 (0.46) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL4101559 | 0.82 | SREBF2 (0.48) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL28208711 | 0.79 | KCNH2 (0.44) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL7468603 | 0.78 | KCNH2 (0.51) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL7958916 | 0.78 | TRPV3 (0.45) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL28853231 | 0.78 | MAPT (0.42) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL27135558 | 0.78 | MAPT (0.42) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL7968990 | 0.78 | KMT2A (0.42) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL11298035 | 0.77 | KCNH2 (0.54) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL3260707 | 0.76 | NR1H2 (0.46) | MEN1MAPTKMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2726479-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2013000994-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-01-03 | — | — | WO | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | HRH1 2972/4885MEN1 4110/4885MAPT 1973/4885 |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | HRH1 2972/4885MEN1 4110/4885MAPT 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.